Spiriva’s (Netherlands') approved indication is for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease - COPD
(including chronic bronchitis and emphysema)
Daxas'®
EUROPEAN approved indication is for the maintenance treatment of severe
chronic obstructive pulmonary disease (COPD) (FEV1 post-brochodilator
less then 50% predicted) associated with chronic bronchitis in patients with
a history of frequent exacerbations as add on to bronchodilator
treatment